share_log

Silverarc Capital Management LLC Purchases 25,535 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Silverarc Capital Management LLC Purchases 25,535 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

银弧资本管理有限责任公司购买25,535股Crinetics制药公司(纳斯达克代码：CRNX)
Financial News Live ·  2022/10/05 14:52

Silverarc Capital Management LLC grew its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 22.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,539 shares of the company's stock after purchasing an additional 25,535 shares during the quarter. Crinetics Pharmaceuticals makes up approximately 0.8% of Silverarc Capital Management LLC's portfolio, making the stock its 28th largest holding. Silverarc Capital Management LLC owned 0.26% of Crinetics Pharmaceuticals worth $2,602,000 as of its most recent filing with the Securities & Exchange Commission.

据Crinetics制药公司(纳斯达克代码：CRNX-GET评级)在提交给美国证券交易委员会的最新披露中称，该公司在第二季度的持股比例增加了22.4%。该公司在本季度额外购买了25,535股后，拥有139,539股公司股票。Crinetics制药公司约占SilverarcCapital Management LLC投资组合的0.8%，使该股成为其第28大持股。截至最近提交给美国证券交易委员会的文件，SilverarcCapital Management LLC拥有Crinetics PharmPharmticals 0.26%的股份，价值2,602,000美元。

A number of other institutional investors also recently modified their holdings of the company. Group One Trading L.P. increased its position in Crinetics Pharmaceuticals by 31.6% during the first quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock worth $161,000 after acquiring an additional 1,759 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Crinetics Pharmaceuticals by 17.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock worth $164,000 after acquiring an additional 1,110 shares during the period. PDT Partners LLC bought a new position in Crinetics Pharmaceuticals during the first quarter worth $220,000. DekaBank Deutsche Girozentrale increased its position in Crinetics Pharmaceuticals by 9.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,300 shares of the company's stock worth $215,000 after acquiring an additional 1,000 shares during the period. Finally, GSA Capital Partners LLP increased its position in Crinetics Pharmaceuticals by 20.8% during the first quarter. GSA Capital Partners LLP now owns 14,897 shares of the company's stock worth $327,000 after acquiring an additional 2,562 shares during the period. Institutional investors own 94.42% of the company's stock.

其他一些机构投资者最近也调整了对该公司的持股。第一集团贸易公司在第一季度将其在Crinetics制药公司的头寸增加了31.6%。Group One Trading L.P.在此期间增持了1,759股，现在拥有7,318股该公司股票，价值161,000美元。Zurcher Kantonalbank苏黎世广东银行在第一季度将其在Crinetics PharmPharmticals的头寸增加了17.4%。Zurcher Kantonalbank苏黎世广东银行在此期间额外收购了1110股，现在拥有7493股该公司股票，价值16.4万美元。PDT Partners LLC在第一季度购买了Crinetics PharmPharmticals的一个新头寸，价值22万美元。德意志银行第一季度将其在Crinetics PharmPharmticals的头寸增加了9.7%。DekaBank Deutsche Girozentale在此期间增持了1,000股，目前持有11,300股该公司股票，价值21.5万美元。最后，GSA Capital Partners LLP在第一季度将其在Crinetics制药公司的头寸增加了20.8%。GSA Capital Partners LLP在此期间额外购买了2562股，现在拥有14,897股该公司股票，价值327,000美元。机构投资者持有该公司94.42%的股票。

Get
到达
Crinetics Pharmaceuticals
Crinetics制药公司
alerts:
警报：

Crinetics Pharmaceuticals Trading Down 3.0 %

Crinetics制药公司股价下跌3.0%

Crinetics Pharmaceuticals stock traded down $0.58 on Wednesday, hitting $18.47. The company's stock had a trading volume of 4,668 shares, compared to its average volume of 248,631. The company has a fifty day moving average price of $20.33 and a 200-day moving average price of $20.11. Crinetics Pharmaceuticals, Inc. has a one year low of $15.91 and a one year high of $28.95.

周三，Crinetics PharmPharmticals的股价下跌0.58美元，触及18.47美元。该公司股票的成交量为4,668股，而其平均成交量为248,631股。该公司的50日移动平均价为20.33美元，200日移动平均价为20.11美元。Crinetics PharmPharmticals，Inc.的一年低点为15.91美元，一年高位为28.95美元。

Insider Buying and Selling at Crinetics Pharmaceuticals

Crinetics PharmPharmticals的内幕买卖

In other Crinetics Pharmaceuticals news, Director Matthew K. Fust sold 5,700 shares of the business's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $20.96, for a total value of $119,472.00. Following the sale, the director now owns 12,536 shares of the company's stock, valued at approximately $262,754.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at
在Crinetics PharmPharmticals的其他新闻中，董事马修·K·福斯特在7月13日星期三的一次交易中出售了5,700股该公司的股票。这些股票的平均价格为20.96美元，总价值为119,472.00美元。交易完成后，董事现在持有该公司12,536股股票，价值约262,754.56美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在
this link
这个环节
. In other news, insider Stephen F. Betz sold 4,168 shares of the business's stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $21.01, for a total value of $87,569.68. Following the sale, the insider now owns 100,598 shares in the company, valued at approximately $2,113,563.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through
。在其他新闻方面，内部人士斯蒂芬·F·贝茨在9月15日星期四的一次交易中出售了4168股该公司的股票。这些股票的平均价格为21.01美元，总价值为87,569.68美元。出售后，这位内部人士现在拥有该公司100,598股，价值约2,113,563.98美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过
the SEC website
美国证券交易委员会网站
. Also, Director Matthew K. Fust sold 5,700 shares of the business's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $20.96, for a total transaction of $119,472.00. Following the completion of the sale, the director now owns 12,536 shares in the company, valued at approximately $262,754.56. The disclosure for this sale can be found
。此外，董事马修·K·福斯特在7月13日(星期三)的一次交易中出售了5,700股该公司股票。这些股票以20.96美元的平均价格出售，总成交金额为119,472.00美元。出售完成后，董事现在拥有该公司12,536股，价值约262,754.56美元。关于这次销售的披露可以找到
here
这里
. Insiders have sold 12,062 shares of company stock valued at $252,770 in the last 90 days. 5.90% of the stock is currently owned by company insiders.
。在过去的90天里，内部人士已经出售了12,062股公司股票，价值252,770美元。5.90%的股份目前由公司内部人士持有。

Crinetics Pharmaceuticals Profile

Crinetics制药公司简介

(Get Rating)

(获取评级)

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).

Crinetics制药公司是一家临床阶段制药公司，专注于罕见内分泌疾病和内分泌相关肿瘤治疗药物的发现、开发和商业化。它的主要候选产品是Paltusotine，这是一种口服选择性非肽生长抑素受体2型激动剂，已经完成了治疗肢端肥大症的第三阶段临床试验，以及治疗类癌综合征和无功能神经内分泌肿瘤(NETS)的第二阶段临床试验。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
  • Hot Potato: Lamb Weston Stock Confirms a Top
  • Too Soon: 3 Reasons to Wait on DocuSign Stock
  • Rite-Aid Sings a Familiar Tune That Investors Don't Want to Hear
  • Don't Give Up on These Q3 Losers
  • The Anatomy of a Great Pension Plan
  • 免费获取StockNews.com的Crinetics PharmPharmticals研究报告(CRNX)
  • 辣土豆：韦斯顿羊肉库存涨幅居前
  • 太快：等待DocuSign股票的三个理由
  • 礼仪援助唱出了投资者不愿听到的熟悉曲调
  • 不要放弃这些第三季度的失败者
  • 一个伟大的养老金计划的剖析

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

获得《Crinetics PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Crinetics制药和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发